Alexion to acquire Pfizer’s rare disease gene therapies for $1bn

Alexion will obtain access to a number of new adeno-associated virus capsids.

Vishnu Priyan July 31 2023

Research group Alexion, AstraZeneca Rare Disease has signed a definitive agreement for acquiring and licensing Pfizer’s early-stage gene therapy portfolio for rare diseases.

Alexion will make a payment of $1bn, aside from sales-based royalty payments, to acquire the preclinical gene therapy assets.

The acquisition also comprises enabling technologies. Alexion will gain access to a number of new adeno-associated virus (AAV) capsids, which are an efficient approach offering therapeutic gene cargos in gene therapies and gene editing processes.

The latest asset acquisition will enhance the combined expertise of Alexion and AstraZeneca in genomic therapy. 

Alexion CEO Marc Dunoyer stated: “The announcement represents another major step forward in Alexion and AstraZeneca’s ambition to be an industry leader in genomic medicine, which has the potential to be transformative and even curative for patients with devastating diseases. 

“We look forward to continuing our work to develop enhanced platforms and technologies with broad therapeutic applications while integrating best-in-class expertise to accelerate promising therapeutics into the clinic.”

The deal will conclude in the third quarter of 2023.

In 2022, AstraZeneca acquired LogicBio to create novel genetic therapies with enhanced safety and efficacy profiles. 

The company reported total revenue of $11.4bn in the second quarter (Q2) of 2023 compared to $10.77bn in the prior year's Q2, a 6% rise.

Core earnings per share rose by 25% for the quarter, to $2.15.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close